A Study in Healthy Volunteers to Evaluate the Drug-Drug Interaction Potential of CCX168 With Concomitant Medications

NCT06004947 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

32

Enrollment

INDUSTRY

Sponsor class

Conditions

Anti-neutrophil Cytoplasmic Antibody-associated Vasculitis

Interventions

DRUG: CCX168
DRUG: Midazolam
DRUG: Celecoxib
DRUG: Itraconazole
DRUG: Rifampicin

Sponsor

Amgen